Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating [Yahoo! Finance]
CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at Cantor Fitzgerald from $6.00 to $10.00. They now have an "overweight" rating on the stock.
CytomX Therapeutics to Present at Upcoming February Conferences [Yahoo! Finance]
CytomX Therapeutics to Present at Upcoming February Conferences
CytomX Therapeutics (NASDAQ:CTMX) was given a new $10.00 price target on by analysts at Barclays PLC.